← Leaderboards
Richard B. Moss
Stanford University
$489,358
Attributed
$489,358
Total exposure
18
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $34.7K · FY2005–08$50K$37.5K$25K$12.5K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$489,358 · 18
By mechanism
M01$489,358 · 18
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Marlene Rabinovitch$40,032,014
- Stephen J Galli$26,066,229
- Roham Zamanian$6,654,663
- Garry P Nolan$53,568,535
- Jayakar V Nayak$2,392,495
Others in their field
Top investigators on “Cystic Fibrosis”
- John F Engelhardt · University Of Iowa$42,933,706
- Michael R Knowles · University Of North Carolina Chapel Hill$30,250,682
- David A Stoltz · University Of Iowa$25,455,359
- Joseph Zabner · University Of Iowa$25,382,103
- Paul B McCray · University Of Iowa$25,146,293
- Richard C Boucher · University Of North Carolina Chapel Hill$24,890,955
Research focus
Cystic FibrosisClinical ResearchHuman SubjectHuman Therapy EvaluationDrug Screening /EvaluationInstitutionGrantFundingUnited States National Institutes Of HealthSourceResourcesResearch PersonnelComputer Retrieval Of Information On Scientific Projects DatabaseInhalation Drug AdministrationClinical Trial Phase IDoseSafetyMetabolism Disorder ChemotherapyDosagePharmacokineticsCystic Fibrosis PatientsAdeno Associated Virus GroupElastase InhibitorAntibiotics
Grant awards (24)
CLINICAL TRIAL: TETRASODIUM IN PATIENTS WITH MILD CYSTIC FIBROSIS LUNG DISEASE$4,778
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: VX-770 CFTR ACTIVITY IN CYSTIC FIBROSIS (CF) SUBJECTS WITH GENOT$1,024
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: XOLAIR IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS WIT$341
M01 · FY2008 · RR · contact PI
PTC124 AS AN ORAL TREATMENT FOR NONSENSE-MUTATION-MEDIATED CYSTIC FIBROSIS$14,044
M01 · FY2007 · RR · contact PI
A PHASE I/II, SINGLE-CENTER, BLINDED, RANDOMIZED, CONTROLLED STUDY OF XOLAIR$8,193
M01 · FY2007 · RR · contact PI
DIABETES THERAPY IN CF PATIENTS WITH ABNORMAL GLUCOSE TOLERANCE$1,171
M01 · FY2007 · RR · contact PI
EVALUATE ANTI-INFLAMMATORY AGENTS IN PATIENTS WITH CYSTIC FIBROSIS$1,171
M01 · FY2007 · RR · contact PI
XOLAIR IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH FOOD ALLERGY$18,681
M01 · FY2006 · RR · contact PI
(INS37217) INHALATION SOLUTION IN PATIENTS WITH CYSTIC FIBROSIS LUNG DISEASE$8,896
M01 · FY2006 · RR · contact PI
HETEROGENEITY AMONG HUMAN CD4+ T-CELL CLONES$3,113
M01 · FY2006 · RR · contact PI
TO EVALUATE ANTI-INFLAMMATORY AGENTS IN PATIENTS WITH CYSTIC FIBROSIS$2,669
M01 · FY2006 · RR · contact PI
DIABETES THERAPY IN CF PATIENTS WITH ABNORMAL GLUCOSE TOLERANCE$1,334
M01 · FY2006 · RR · contact PI
TREATMENT WITH BIIL 284 BS IN ADULT AND PEDIATRIC CYSTIC FIBROSIS PATIENTS$18,042
M01 · FY2005 · RR
DIABETES THERAPY IN CYSTIC FIBROSIS PATIENTS WITH ABNORMAL GLUCOSE TOLERANCE$669
M01 · FY2005 · RR
PHASE IIA TO EVALUATE LUNG BIOEFFICACY OF DMP777 IN ADULTS W/ Cystic Fibrosis$134,676
M01 · FY2001 · RR
ASCENDING INHALED DOSES OF IB 367 IN CYSTIC FIBROSIS$134,676
M01 · FY2001 · RR
AEROSOLIZED TGAAVCF FOR CYSTIC FIBROSIS THERAPY$134,676
M01 · FY2001 · RR
AEROSOLIZED TGAAVCF FOR CYSTIC FIBROSIS THERAPY$0
M01 · FY2001 · RR
ASCENDING INHALED DOSES OF IB 367 IN CYSTIC FIBROSIS$0
M01 · FY2001 · RR
PHASE IIA TO EVALUATE LUNG BIOEFFICACY OF DMP777 IN ADULTS W/ Cystic Fibrosis$0
M01 · FY2001 · RR
PHASE IIA TO EVALUATE LUNG BIOEFFICACY OF DMP777 IN ADULTS W/ Cystic Fibrosis$602
M01 · FY2000 · RR
PHASE II STUDY OF MULTIPLE DOSES OF DMP-777 IN ADULTS WITH CYSTIC FIBROSIS$602
M01 · FY2000 · RR
ASCENDING INHALED DOSES OF IB 367 IN CYSTIC FIBROSIS$0
M01 · FY2000 · RR
AEROSOLIZED TGAAVCF FOR CYSTIC FIBROSIS THERAPY$0
M01 · FY2000 · RR